Home
>
US Stocks
>
Sorrento Therapeutics Inc
Sorrento Therapeutics Inc
SRNE

Sorrento Therapeutics Inc

$6.7225.66%

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open
6.7
Today Low/High
6.7 / 6.8
52 Week Low/High
$5.17 / $17.25
Market Cap
$2.54B

Company Details

Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases. Sorrento's multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies ('G-MAB™library'), clinical stage immuno-cellular therapies ('CAR-T', 'DAR-T'), antibody-drug conjugates ('ADCs'), and clinical stage oncolytic virus ('Seprehvir®'). Sorrento is also developing potential coronavirus antiviral therapies and vaccines, including COVIDTRAP™, ACE-MAB™, COVI-MAB™, COVI-GUARD™, COVI-SHIELD™and COVI-CELL™. Sorrento's commitment to life-enhancing therapies for patients is also demonstrated by its effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin ('RTX'), and ZTlido® (lidocaine topical system) 1.8% for the treatment of post-herpetic neuralgia. RTX is completing a phase IB trial for intractable pain associated with cancer and a phase 1B trial in osteoarthritis patients. ZTlido® was approved by the FDA on February 28, 2018.
Organisation
Sorrento Therapeutics Inc
Headquaters
San Diego, California, US
Employees
502
Industry
Health Technology
CEO
Henry Ji

Discover more

Frequently Asked Questions

What is Sorrento Therapeutics Inc share price today

Can Indians buy Sorrento Therapeutics Inc shares?

How can I buy Sorrento Therapeutics Inc shares from India?

Can Fractional shares of Sorrento Therapeutics Inc be purchased?

What are the documents required to start investing in Sorrento Therapeutics Inc stocks?

We are a SEBI registered investement advisor